Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) EBT (2023 - 2026)

Alto Neuroscience has reported EBT over the past 4 years, most recently at -$26.1 million for Q1 2026.

  • Quarterly results put EBT at -$26.1 million for Q1 2026, down 80.81% from a year ago — trailing twelve months through Mar 2026 was -$73.9 million (down 18.42% YoY), and the annual figure for FY2025 was -$62.2 million, down 1.79%.
  • EBT reached -$26.1 million in Q1 2026 per ANRO's latest filing, down from -$16.1 million in the prior quarter.
  • Across five years, EBT topped out at -$7.3 million in Q1 2023 and bottomed at -$26.1 million in Q1 2026.
  • Median EBT over the past 4 years was -$14.4 million (2025), compared with a mean of -$14.3 million.
  • The largest annual shift saw EBT crashed 82.47% in 2024 before it rose 15.93% in 2025.
  • Over 4 years, EBT stood at -$11.4 million in 2023, then tumbled by 33.49% to -$15.2 million in 2024, then decreased by 5.75% to -$16.1 million in 2025, then crashed by 62.56% to -$26.1 million in 2026.
  • Business Quant data shows EBT for ANRO at -$26.1 million in Q1 2026, -$16.1 million in Q4 2025, and -$14.1 million in Q3 2025.